Regeneron Pharmaceuticals is set to expand its portfolio by acquiring the consumer genetics segment of 23andMe for $256 million. This acquisition follows 23andMe's filing for Chapter 11 bankruptcy, signaling a strategic move by Regeneron to integrate consumer genetics into their healthcare offerings. The deal highlights the growing importance of genetics in developing personalized medical treatments and is expected to enhance Regeneron's capabilities. This swift transaction marks a significant shift in the biotech landscape.